National Center for Advancing Translational Sciences; Amended Notice of Meeting

---
identifier: "/us/fr/2023-25885"
source: "fr"
legal_status: "authoritative_unofficial"
title: "National Center for Advancing Translational Sciences; Amended Notice of Meeting"
title_number: 0
title_name: "Federal Register"
section_number: "2023-25885"
section_name: "National Center for Advancing Translational Sciences; Amended Notice of Meeting"
positive_law: false
currency: "2023-11-24"
last_updated: "2023-11-24"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2023-25885"
document_type: "notice"
publication_date: "2023-11-24"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "88 FR 82386"
fr_volume: 88
---


#  National Center for Advancing Translational Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Center for Advancing Translational Sciences Special Emphasis Panel, Preclinical Proof of Concept Studies for Rare Diseases (R21) January 24, 2024, 9:00 a.m. to January 25, 2024, 5:00 p.m., National Institutes of Health, National Center for Advancing Translational Sciences, 6701 Democracy Boulevard, Bethesda, MD, 20892 which was published in the *Federal Register* on November 14, 2023, FR DOC 2023-25070, 88 FR 78052.

The meeting is being rescheduled due to panel member availability. The meeting will be held on February 1, 2024, 9:00 a.m. to February 2, 2024, 5:00 p.m. This meeting will be held virtually. The meeting is closed to the public.

Dated: November 17, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.